Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutated Lung Adenocarcinoma”

75 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 75 results

Testing effectiveness (Phase 2)Study completedNCT01610336
What this trial is testing

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 161
Not applicableEnded earlyNCT01363557
What this trial is testing

Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis

Who this might be right for
EGFR-mutated Lung AdenocarcinomaBrain Metastasis
Assistance Publique - Hôpitaux de Paris 1
Not applicableUnknownNCT03071705
What this trial is testing

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small Cell AdenocarcinomaTyrosine Kinase MutationEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico 120
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Testing effectiveness (Phase 2)Study completedNCT03544814
What this trial is testing

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Who this might be right for
Lung AdenocarcinomaEGFR Activating Mutation
Shanghai Chest Hospital 99
Large-scale testing (Phase 3)Study completedNCT01719536
What this trial is testing

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Who this might be right for
NSCLC
Betta Pharmaceuticals Co., Ltd. 296
Testing effectiveness (Phase 2)Study completedNCT01466660
What this trial is testing

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Who this might be right for
Lung Neoplasms
Boehringer Ingelheim 319
Not applicableStudy completedNCT01106781
What this trial is testing

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 591
Not applicableUnknownNCT01100827
What this trial is testing

A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
NSCLC
National University Hospital, Singapore
Large-scale testing (Phase 3)Study completedNCT01121393
What this trial is testing

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungAdenocarcinoma
Boehringer Ingelheim 364
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Not applicableUnknownNCT05527808
What this trial is testing

A Single-arm Exploratory Study of Neoadjuvant Therapy

Who this might be right for
Lung Adenocarcinoma
Jun Liu 28
Not applicableStudy completedNCT04795245
What this trial is testing

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 805
Very early researchUnknownNCT03662477
What this trial is testing

Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation

Who this might be right for
NK Cell Mediated Immunity
Shenzhen Fifth People's Hospital 10
Testing effectiveness (Phase 2)Study completedNCT00344773
What this trial is testing

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Pulmonary Cancer
AstraZeneca 46
Not applicableUnknownNCT04122833
What this trial is testing

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Who this might be right for
Adenocarcinoma of LungEGFR Activating Mutation
Konkuk University Medical Center 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802876
What this trial is testing

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Who this might be right for
MSI-H Colorectal CancerMelanomaAnal Carcinoma+28 more
SOLTI Breast Cancer Research Group 184
Not applicableNot Yet RecruitingNCT07287904
What this trial is testing

Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationAdenocarcinoma Lung+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1,000
Not applicableStudy completedNCT02148380
What this trial is testing

Combination of Chemotherapy and Gefitinib as First-line Treatment

Who this might be right for
Non-Small-Cell Lung Cancer
Baohui Han 121
Next Page